Swedish metacarpophalangeal standards compared with previously published norms.

Purpose: Metacarpophalangeal lengths are used to create pattern profiles that are useful for assessment of skeletal dysplasias and malformation syndromes. The purpose of this study was to establish Swedish standards and compare them with previously published norms.

Material And Methods: A group of healthy Swedish children was followed longitudinally from the age of 1 month to 18 years.

Total body bone mineral measurements in children with Prader-Willi syndrome: the influence of the skull's bone mineral content per area (BMA) and of height.

Background. The aim of this study was to investigate the influence of body height and growth on total body measurements with dual energy X-ray absorptiometry (DEXA) in children. Material and methods.

Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably.

We have compared the growth and the body composition in children with Prader-Willi syndrome (PWS) with and without growth hormone treatment (recombinant GH 0.1 IU/kg/day) after a 1-y period. Twenty-nine prepubertal children with PWS, with mean body mass index (BMI) SDS of 2.

Magnetic resonance imaging of anal sphincters after reconstruction of high or intermediate anorectal anomalies with posterior sagittal anorectoplasty and fistula-preserving technique.

Background/purpose: Internal anal sphincter (IAS) function can be expected in approximately 75% of cases of high or intermediate anorectal anomaly reconstruction if the fistula region is preserved and transposed to become the new anal canal.

Methods: To investigate the morphology of the IAS structure, magnetic resonance (MR) imaging was performed postoperatively in 14 patients operated on with posterior sagittal anorectoplasty (PSARP) and fistula-preserving technique. The results were compared with the appearance of the anal canal in seven normal children.

Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome: a preliminary report. The Swedish National Growth Hormone Advisory Group.

A controlled, randomized study was conducted to assess the effect of growth hormone (GH) treatment on growth, body composition and behaviour in prepubertal children (3-12 years of age) with Prader-Willi syndrome. GH treatment was given to one group of 15 patients (group A) at a dose of 0.1 IU/kg/day for 2 years.